From the *Center for Pharmacoeconomic Research and Departments of Pharmacy Practice and Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois; †Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, Illinois; ‡Institute for Community Medicine, University of Greifswald, Greifswald, Germany; and §Evanston Northwestern Healthcare, Center of Outcomes Research and Education (CORE), Northwestern University, Evanston, Illinois.
The authors are grateful for partial funding support from the EuroQol group. The original data collection that focused on the validation of symptom assessment scales in cancer was supported by a consortium of 10 pharmaceutical companies.
Presented at the annual International Society for Quality of Life Research conference in Lisbon, Portugal, Oct 11–14th 2006, and an earlier version of the paper may appear in the proceedings of the 24th Scientific Plenary of the EuroQol Group.
The views expressed in this work are the solely those of the authors and do not necessarily represent the views of the EuroQol Group. The 5L version of the EQ-5D was an experimental prototype and is not an officially recognized version distributed by the EuroQol Group.
Reprints: A. Simon Pickard, PhD, Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Rm 164, MC 886, 833 South Wood Street, Chicago, IL 60612. E-mail: [email protected].
